Recovery, growth hormone optimization, visceral-fat reduction, mitochondrial efficiency, and longevity — built from the literature, prescribed by a physician, sourced from licensed compounding pharmacies, and monitored on a defined schedule.
We do not run a one-size protocol. Every patient receives a peptide stack matched to a clinical question — recovery from injury, body composition stalled despite training, declining sleep architecture, or a longevity-focused floor on age-related decline.
A complementary approach for tendon, ligament, and soft-tissue recovery — supporting angiogenesis, cell migration, and fascial repair. Considered for stalled injuries and post-surgical recovery. Specific agents are selected on an individual basis after evaluation.
Best fit: athletes with chronic tendinopathy, post-op patients, anyone whose recovery has plateaued despite PT.
Read the regulatory update →An FDA-approved GHRH analog with the deepest human evidence base in this class. Restores a more physiologic GH/IGF-1 axis, drives visceral-fat reduction, and supports sleep architecture and lean mass — without the supraphysiologic exposure of exogenous HGH. Where tesamorelin is not indicated, additional GH-axis support peptides may be considered on an individual basis, subject to partner-pharmacy formulary at the time of prescribing.
Best fit: men and women 35+ with declining sleep quality, slow recovery, or body composition stalled despite training — particularly those with central adiposity or a documented low IGF-1.
Why tesamorelin first. Limitless leads growth-hormone-axis prescribing with tesamorelin because it is FDA-approved and carries the deepest evidence in its class. Other GH-axis support peptides are considered only on an individual basis and only where a licensed compounding partner can lawfully supply them. We do not represent any non-approved peptide as FDA-approved. See our June 2026 regulatory status read.
Read the protocol →A GHRH analog with the strongest evidence base for targeted reduction of visceral adipose tissue (VAT). Originally FDA-approved for HIV-associated lipodystrophy; now used clinically for metabolically active belly fat that resists diet and training.
Evidence Update — May 2026. A pooled meta-analysis of five randomized controlled trials reports a mean reduction of −27.7 cm² in visceral adipose tissue and an increase of +1.42 kg in lean body mass. More recent ART-era data show roughly 5% lower hepatic fat versus placebo, with concurrent improvements in triglycerides and CRP. A new 2026 randomized trial in patients on modern integrase-inhibitor (INSTI) regimens reports a median 16% VAT reduction at 12 months, with roughly two-thirds of treated patients meeting the clinical-responder threshold and no worsening of glycemic control. Fat quality improves independent of fat quantity — adipose-tissue density rises as VAT volume falls. Read the fat-quality analysis →
Best fit: patients on a GLP-1 plateau, "skinny visceral" lean-BMI patients with central adiposity, or MASLD/NAFLD with mild-to-moderate hepatic steatosis.
Read the protocol →A class of mitochondrial-derived peptides that engage AMPK — the same energy-sensing pathway activated by exercise and metformin. Considered to support mitochondrial efficiency, glucose handling, and exercise tolerance. The inside-the-cell complement to NAD+. Specific agents are selected on an individual basis after evaluation.
Best fit: patients with metabolic inflexibility, fatigue despite normal labs, or longevity-focused stacking.
Read more →The Limitless signature — IV loading at 5 × 750 mg over two weeks, followed by subcutaneous maintenance of 100–200 mg daily or every other day. Restores the substrate that powers DNA repair, mitochondrial output, and sirtuin signaling.
Best fit: recommended on every Limitless protocol — adjusted for renal function and tolerability.
Read the protocol →A centrally acting libido peptide for low libido in both men and women, used selectively when desire is the primary concern and hormone optimization alone has not closed the gap. Prescribed only when specifically indicated — never by default, and only where lawful.
Best fit: ask Dr. Hare during your visit if libido is a priority concern.
Discuss at consultation →Research-stage cognitive/longevity peptides target attention, anxiety, and synaptogenesis. The mechanisms are interesting; the human evidence is mixed. We publish our evaluation framework so you can think about them the way we do — under physician oversight, sourced through licensed 503A only.
Best fit: patients reading about nootropic peptides who want a physician's read before they buy from the gray market.
Read the framework →Every peptide originates from a state-licensed 503A pharmacy or FDA-registered 503B outsourcing facility. The pharmacy of origin is in your portal — we can name the source on request.
A peptide is prescribed only after evaluation, lab review, and a documented clinical indication. We don't sell peptides at the front desk — they're prescribed and dispensed.
Each protocol carries a written monitoring plan: baseline labs, follow-up labs, symptom check-ins, stop criteria. The plan is in your portal before the first dose.
Every Limitless protocol has a public, physician-authored research summary. Open the underlying evidence before you decide.
What the PCAC is actually evaluating on July 23, 2026 — and how Limitless prescribes tissue-repair peptides inside the uncertainty.
Read summary →Pooled five-trial result: −27.7 cm² VAT, +1.42 kg lean mass, with a cognitive-endpoint signal. What it does and does not support.
Read summary →NR/NMN RCTs, IV pharmacokinetic data, and the precursor literature. What the 5×750 mg loading protocol actually rests on.
Read summary →A physician's response to the CNN and Topol skepticism. Three evidence tiers, six prescribing rules, and what we deliberately don't prescribe.
Read summary →Limitless is a peptide-forward practice, but the best longevity protocols don't pretend a single class of molecules answers every question. Daily low-dose tadalafil sits alongside the peptide menu as our standing recommendation for endothelial, urinary, and erectile-health protection in men 35–75 with no contraindication.
A long-acting PDE5 inhibitor used as a daily pathway-level medication, not an on-demand pill. Continuous nitric-oxide signaling supports endothelial function, lower urinary tract symptoms, erectile preservation, and an emerging cognitive-protection signal. FDA-approved for daily use in BPH and ED. Generic, inexpensive, well-tolerated.
Best fit: men 35–75 with vascular risk factors, BPH, post-prostatectomy, or on TRT — and no nitrate, hypotension, or specific ophthalmologic contraindication.
Read the protocol →Compounded peptides are prescription therapeutics — not retail supplements. They carry real benefit and real risk. We mitigate risk with documented sourcing, evaluation, lab monitoring, and clear stop criteria. Anyone taking peptides without a physician's oversight is not in the safer lane.
Peptide-by-peptide. NAD+ patients often notice energy and clarity inside the first IV loading window. Recovery stacks (BPC/TB) typically show within 2–6 weeks. GH-secretagogue and Tesamorelin protocols are 12–16 week conversations.
Compounded peptides are typically not covered by insurance. We provide transparent self-pay pricing and itemized receipts. Many patients use HSA/FSA funds.
No protocol at Limitless is indefinite by default. Each carries a defined cycle, planned re-evaluation, and an exit point. We optimize, then we taper or stop and reassess.
A 30-minute consultation, a full lab panel, and a physician-built protocol — sourced, prescribed, and monitored to a documented standard.